Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 80425-0449

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 80425-0449). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rabeprazole Sodium Dr 20mg Tablet #30 (Rabeprazole Sodium Dr 20mg 80425 0449 01)

RABEPRAZOLE SODIUM DR 20 MG TABLET label for a 30-count package. The label shows Advanced Rx of Tennessee, LLC as the packer and includes drug identification details including NDC 80425-0449-01. Storage instructions specify 20°-25°C (68°-77°F). The label references comparison to Aciphex and includes expiration date 3/31/2027. Manufacturer is indicated as ADVAGEN PHARMA S/N: 000001.*

FDA Label Image

Rabeprazole Sodium Dr 20mg Tablet #60 (Rabeprazole Sodium Dr 20mg 80425 0449 02)

Label for Rabeprazole Sodium Delayed Release 20 mg tablet, packaged by Advanced Rx, Nashville, TN. The label includes barcode, NDC 80425-0449-02, lot number, expiration date 3/31/2027, and reference to comparison with Aciphex. Labeler is Advanced Rx of Tennessee, LLC.*

FDA Label Image

Rabeprazole Sodium Dr 20mg Tablet #90 (Rabeprazole Sodium Dr 80425 0449 03)

Label for RABEPRAZOLE SODIUM 20 mg delayed-release tablets from Advanced Rx of Tennessee, LLC. It includes storage instructions (20°-25°C), a caution against transfer, NDC 80425-0449-03, a lot number, and expiration date 3/31/2027. Also shows manufacturer Advagen Pharma with an Rx only designation.*

FDA Label Image

Structural Image (Rabeprazole Dr Tablet 01)

Chemical structure of rabeprazole sodium, showing its molecular framework including a pyridine ring, sulfoxide group, and ether substituents.*

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 02)

A line graph depicting mean heartburn scores over a study day period for three groups: placebo, RAB 10 mg, and RAB 20 mg. Heartburn scores range from 0 (None) to 4 (Very Severe), showing changes before and after the study day (day 0).*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 03)

A line graph showing mean heartburn scores over study days for three groups: placebo, rabeprazole 10 mg, and rabeprazole 20 mg. The x-axis represents study days with a vertical line at day 0, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). The graph tracks symptom changes before and after the study start for each group.*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 04)

A line graph comparing mean heartburn scores over a 28-day period for two groups: placebo (n=58) and rabeprazole sodium 20 mg (n=59). The x-axis represents study days, and the y-axis shows heartburn severity scores from 0 (none) to 4 (very severe). The graph displays a decrease in heartburn scores over time for the rabeprazole group compared to placebo.*

FDA Label Image

Figure 5: Mean Nighttime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 05)

A line graph depicting mean heartburn scores over a study period of 42 days with study days on the x-axis and mean score on the y-axis. Two groups are compared: placebo (n=58) and rabeprazole sodium 20 mg (n=59), showing trends in heartburn severity from day -14 to day 28.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.